Antibe - A low risk buyAntibe is either doing 'B' or has probably bottomed out. Trend lines and crossovers also support an up move. Very likely to hit the 1st target. Could hit the second and continue the up move if the +ve divergence stays.Longby XtanlyUpdated 112
inverse head and shouldersOn the daily we have the rsi above the 50 level pointing up up and a macd kiss on the positive side. Looking at the price action we can see the price action above the 8, 21, and 55 ema , but will under the 200 ema, as well as a neckline for a possible inverse head and shoulders breakout. They have just up listed to the TSX with potential to uplist to the NASDAQ. They may also potentially be picked up by big pharm . Insider buying occurred at around 0.34 before the wedge broke bullish. This area is likely a major dip opportunity, where in coming years you wished you picked up some shares at these prices. It's revolutionary product for NSAID could be huge in the medical community. Longby gNnairdA222
$ATBPF Antibe Therapeutics Inc, bull run to continue?Trade opportunity to the top of a well defined channel, with a possible 13% gain. Indicators quite bullish as MACD reverses of the zero line, histogram ticking higher and green. RSI in strong move. Company profile Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. It operates through the Antibe Therapeutics, and Citagenix segments. The Antibe Therapeutics segment focuses on the development of pharmaceutical products. The Citagenix segment involves in the development and sale of regenerative medicines serving the dental and orthopedic market places. The company was founded by Andre Buret, John Wallace and Giuseppe Cirino on May 5, 2009 and is headquartered in Toronto, Canada. Longby OTCMarketsExpert15